Base de dados : MEDLINE
Pesquisa : C02.782.580.600.500.500 [Categoria DeCS]
Referências encontradas : 10925 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1093 ir para página                         

  1 / 10925 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29447169
[Au] Autor:Eom H; Park Y; Kim J; Yang JS; Kang H; Kim K; Chun BC; Park O; Hong JI
[Ad] Endereço:Division of Vaccine-Preventable Diseases Control and National Immunization Program, Korea Center for Disease Control and Prevention, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
[Ti] Título:Occurrence of measles in a country with elimination status: Amplifying measles infection in hospitalized children due to imported virus.
[So] Source:PLoS One;13(2):e0188957, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Republic of Korea declared measles elimination in 2006. However, a measles outbreak occurred in 2013. This study aimed to identify the epidemiological characteristics of the sources of infection and the pattern of measles transmission in 2013 in South Korea. We utilized surveillance data, epidemiological data, immunization registry data, and genetic information. We describe the epidemiological characteristics of all measles case patients (sex, age distribution, vaccination status, sources of infection) as well as details of the outbreak (the pattern of transmission, duration, mean age of patients, and generation time). In 2013, a total of 107 measles cases were notified. Most patients were infants (43.0%) and unvaccinated individuals (60.7%). We identified 4 imported and 103 import-related cases. A total of 105 cases were related to four outbreaks that occurred in Gyeongnam, northern Gyeonggi, southern Gyeonggi, and Seoul. The predominant circulating genotype was B3 type, which was identified in the Gyeongnam, northern Gyeonggi, and southern Gyeonggi outbreaks. The B3 type had not been in circulation in South Korea in the previous 3 years; virologic evidence suggests that these outbreaks were import-related. Most measles cases in South Korea have been associated with imported measles virus. Although Korea has maintained a high level of herd immunity, clustering of susceptible people can cause such measles outbreaks.
[Mh] Termos MeSH primário: Sarampo/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Pré-Escolar
Surtos de Doenças
Feminino
Hospitalização
Seres Humanos
Lactente
Masculino
República da Coreia/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180216
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188957


  2 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381765
[Au] Autor:Haralambieva IH; Kennedy RB; Simon WL; Goergen KM; Grill DE; Ovsyannikova IG; Poland GA
[Ad] Endereço:Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America.
[Ti] Título:Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination.
[So] Source:PLoS One;13(1):e0191812, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: MicroRNAs are important mediators of post-transcriptional regulation of gene expression through RNA degradation and translational repression, and are emerging biomarkers of immune system activation/response after vaccination. METHODS: We performed Next Generation Sequencing (mRNA-Seq) of intracellular miRNAs in measles virus-stimulated B and CD4+ T cells from high and low antibody responders to measles vaccine. Negative binomial generalized estimating equation (GEE) models were used for miRNA assessment and the DIANA tool was used for gene/target prediction and pathway enrichment analysis. RESULTS: We identified a set of B cell-specific miRNAs (e.g., miR-151a-5p, miR-223, miR-29, miR-15a-5p, miR-199a-3p, miR-103a, and miR-15a/16 cluster) and biological processes/pathways, including regulation of adherens junction proteins, Fc-receptor signaling pathway, phosphatidylinositol-mediated signaling pathway, growth factor signaling pathway/pathways, transcriptional regulation, apoptosis and virus-related processes, significantly associated with neutralizing antibody titers after measles vaccination. No CD4+ T cell-specific miRNA expression differences between high and low antibody responders were found. CONCLUSION: Our study demonstrates that miRNA expression directly or indirectly influences humoral immunity to measles vaccination and suggests that B cell-specific miRNAs may serve as useful predictive biomarkers of vaccine humoral immune response.
[Mh] Termos MeSH primário: Anticorpos Antivirais/biossíntese
Linfócitos B/metabolismo
Vacina contra Sarampo/administração & dosagem
Sarampo/imunologia
MicroRNAs/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Linfócitos B/imunologia
Feminino
Seres Humanos
Lactente
Masculino
Vacina contra Sarampo/imunologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Measles Vaccine); 0 (MicroRNAs)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191812


  3 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457672
[Au] Autor:Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
[Ad] Endereço:Instituto Nacional de Salud Pública, Mexico. Electronic address: jdiaz@insp.mx.
[Ti] Título:Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
[So] Source:Vaccine;35(23):3116-3122, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:IMPORTANCE: In a previous study on booster vaccination, we reported that two aerosolized MMR vaccines were as safe and immunogenic as injectable vaccines containing the same antigens. We now present results of antibody persistence one year after immunization. OBJECTIVE: To assess the antibody persistence for measles, mumps, and rubella one year following booster immunization. METHODS: We performed clinical and serological follow-up of participants in a previous study of Mexican children aged 6-7years, in which participants were randomized to four groups receiving, by aerosolized or by injection, the MMR SII vaccine (Serum Institute of India), or the MMR II (Merck Sharp & Dhome). We evaluated the antibody persistence by PRN test for measles and by ELISA for rubella and mumps. The occurrence of clinical events was evaluated via periodic visits of a nurse team to children's schools and homes. RESULTS: Of the 260 initial participants, 241 completed one-year follow-up. There were only statistically significant differences in baseline seropositivity for mumps. One year after immunization, seropositivity in all groups was 100% for measles and rubella. The seropositivity rank for mumps was from 90.3% for the injected vaccine MMR II to 96.6% for vaccine MMR SII applied by aerosol; these differences were not statistically significant. With exception of the aerosolized vaccine MMR SII for the geometric mean titer (GMT) for measles, all study groups presented declination of GMT for the three viruses. The difference between the aerosolized vaccines MMR SII and MMR RII was statistically significant for mumps antibodies. Only mild clinical events were identified. CONCLUSION: Under conditions of no endemic transmission for measles and rubella, and of low circulation of mumps virus, school-aged children remained seropositive to the three viruses one year following booster immunization. The study was registered under CMN 2010-005 number at COFEPRIS (National Regulatory Authority).
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Imunização Secundária/métodos
Vírus do Sarampo/imunologia
Vacina contra Sarampo-Caxumba-Rubéola/imunologia
Vírus da Caxumba/imunologia
[Mh] Termos MeSH secundário: Aerossóis
Criança
Ensaio de Imunoadsorção Enzimática
Feminino
Seguimentos
Seres Humanos
Imunização Secundária/efeitos adversos
Índia/epidemiologia
Injeções
Masculino
Sarampo/epidemiologia
Sarampo/imunologia
Sarampo/prevenção & controle
Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem
Vacina contra Sarampo-Caxumba-Rubéola/efeitos adversos
Caxumba/epidemiologia
Caxumba/imunologia
Caxumba/prevenção & controle
Rubéola (Sarampo Alemão)/epidemiologia
Rubéola (Sarampo Alemão)/imunologia
Rubéola (Sarampo Alemão)/prevenção & controle
Vírus da Rubéola/imunologia
Estudos Soroepidemiológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aerosols); 0 (Antibodies, Viral); 0 (Measles-Mumps-Rubella Vaccine); 0 (rubella antibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  4 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390321
[Au] Autor:Bichon A; Aubry C; Benarous L; Drouet H; Zandotti C; Parola P; Lagier JC
[Ad] Endereço:Aix Marseille Univ, CNRS 7278, IRD 198, INSERM 1095, AP-HM, URMITE, IHU Méditerranée-Infection, 19-21 Boulevard Jean Moulin, Marseille Cedex 5.
[Ti] Título:Case report: Ribavirin and vitamin A in a severe case of measles.
[So] Source:Medicine (Baltimore);96(50):e9154, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Despite a vaccine being widely available, measles continues to occur frequently, with sometimes lethal consequences. PATIENTS CONCERNS: The mortality rate reaches 35% and measles represents 44% of the 1.4 million deaths which are due to preventable diseases. Severe forms of measles are reported, mainly in young, unvaccinated adults, and in specific populations. The risk factors for severe measles include no or incomplete vaccination and vitamin A deficiency. Apart from secondary measles-related infections, severe measles is mainly represented by neurological, respiratory, and digestive symptoms. DIAGNOSES: Strengthening the hypothesis that there is a link between vitamin A deficiency and severe measles in this paper we report the case of a 25-year-old unvaccinated man hospitalized for severe and complicated measles. OUTCOMES: The evolution was good after administration of intramuscular vitamin A as well as intravenous ribavirin. LESSONS: Measles remains a fatal and serious disease. The early use of ribavirin and vitamin A shows significant improvements regarding morbimortality and should be systematic in severe cases.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Sarampo/prevenção & controle
Ribavirina/uso terapêutico
Vitamina A/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Masculino
Sarampo/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 11103-57-4 (Vitamin A); 49717AWG6K (Ribavirin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009154


  5 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465158
[Au] Autor:Muñoz-Alía MA; Casasnovas JM; Celma ML; Carabaña J; Liton PB; Fernandez-Muñoz R
[Ad] Endereço:Virology Unit, Ramón y Cajal Hospital, Madrid, Spain.
[Ti] Título:Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies.
[So] Source:Virus Res;236:30-43, 2017 05 15.
[Is] ISSN:1872-7492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Measles virus (MV) remains a leading cause of vaccine-preventable deaths in children. Protection against MV is associated with neutralizing antibodies that preferentially recognize the viral hemagglutinin (MV-H), and to a lesser extent, the fusion protein (MV-F). Although MV is serologically monotypic, 24 genotypes have been identified. Here we report three neutralization epitopes conserved in the more prevalent circulating MV genotypes, two located in the MV-H receptor binding site (RBS) (antigenic site III) and a third in MV-H/MV-F interphase (antigenic site Ia) which are essential for MV multiplication. In contrast, two MV-H neutralization epitopes, showed a genotype-specific neutralization escape due to a single amino acid change, that we mapped in the "noose" antigenic site, or an enhanced neutralization epitope (antigenic site IIa). The monoclonal antibody (mAb) neutralization potency correlated with its binding affinity and was mainly driven by kinetic dissociation rate (k ). We developed an immunoassay for mAb binding to MV-H in its native hetero-oligomeric structure with MV-F on the surface of a MV productive steady-state persistently infected (p.i.) human cell lines, and a competitive-binding assay with serum from individuals with past infection by different MV genotypes. Binding assays revealed that a broad neutralization epitope, in RBS antigenic site, a genotype specific neutralization epitopes, in noose and IIa sites, were immunogenic in natural infection and vaccination and may elicit long-lasting humoral immunity that might contribute to explain MV immunogenic stability. These results support the design of improved measles vaccines, broad-spectrum prophylactic or therapeutic antibodies and MV-used in oncolytic therapies.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Anticorpos Antivirais/imunologia
Hemaglutininas Virais/imunologia
Vírus do Sarampo/imunologia
Sarampo/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/imunologia
Epitopos/administração & dosagem
Epitopos/imunologia
Genótipo
Hemaglutininas Virais/administração & dosagem
Hemaglutininas Virais/genética
Seres Humanos
Sarampo/prevenção & controle
Sarampo/virologia
Vacina contra Sarampo/administração & dosagem
Vacina contra Sarampo/imunologia
Vírus do Sarampo/classificação
Vírus do Sarampo/genética
Vírus do Sarampo/isolamento & purificação
Testes de Neutralização
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Epitopes); 0 (Hemagglutinins, Viral); 0 (Measles Vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  6 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29296151
[Au] Autor:Ismail A; Tabu C; Onuekwusi I; Otieno SK; Ademba P; Kamau P; Koki B; Ngatia A; Wainaina A; Davis R
[Ad] Endereço:American Red Cross, US.
[Ti] Título:Micro-planning in a wide age range measles rubella (MR) campaign using mobile phone app, a case of Kenya, 2016.
[So] Source:Pan Afr Med J;27(Suppl 3):16, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:eng
[Ab] Resumo:Introduction: A Measles rubella campaign that targeted 9 months to 14 year old children was conducted in all the 47 counties in Kenya between 16th and 24th of May 2016. Micro-planning using an android phone-based app was undertaken to map out the target population and logistics in all the counties 4 weeks to the campaign implementation instead of 6 months as per the WHO recommendation. The outcomes of the micro-planning exercise were a detailed micro-plan that served as a guide in ensuring that every eligible individual in the population was vaccinated with potent vaccine. A national Trainer of Trainers training was done to equip key officers with new knowledge and skills in developing micro-plans at all levels. The micro planning was done using a mobile phone app, the doforms that enabled data to be transmitted real time to the national level. The objective of the study was to establish whether use of mobile phone app would contribute to quality of sub national micro plans that can be used for national level planning and implementation of the campaign. Methods: There were 9 data collection forms but only forms 1-7 were to be uploaded onto the app. Forms 8A and 9A were to be filled but were to remain at the implementation level for use intra campaign. The forms were coded; Form 1A&B, 2A, 3A, 4A, 5A, 6A, 7A, 8A and 9A The Village form (form 1A&B) captured information by household which included village names, name of head of household, cell phone contact of head of household, number of children aged 9 months to 14years in the household, possible barriers to reaching the children, appropriate vaccination strategy based on barriers identified and estimated or proposed number of teams and type. This was the main form and from this every other form picked the population figures to estimate other supplies and logistics. On advocacy, communication and social mobilization the information collected included mobile network coverage, public amenities such as churches, mosques and key partners at the local level. On human resource and cold chain supplies the information collected included number of health facilities by type, number of health workers by cadre in facilities within the village, number of vaccine carriers and icepacks by size, refrigerators and freezers. All these forms were to be uploaded onto the phone app. except form 8A, the individual team plan, which was to be used during implementation at the local level. Android phone application, doforms, was used to capture data. Training on micro planning, data entry and doforms app was conducted at National, County, Sub-county and ward levels using standardized guidelines. An interactive case study was used in all the trainings to facilitate understanding. The App was also available on Laptops through its provided web-application. The app allowed multiple users to log in concurrently. Feedback on all the variables were obtained from the team at the Ward level. The ward level team included education officers or teachers, village elders, community health workers and other community stakeholders. Only the Ward level was allowed to collect information on paper and that information was subsequently transferred to the phone-based app, doforms, by health information officers. The national, county and sub county were able to access their data from the app using a password provided by the administrator. Results: Real time data was received from 46 of 47 counties. One county (Marsabit) did not participate in the micro plan process. Over 97% (283/290) of the sub counties responded and shared various information via the app. Different data forms had different completion rates. There was 100% completion rate for the data on villages and target population. Much valuable information was shared but there was no time for the national and county level to interrogate and harmonize for proper implementation. The information captured during the campaign can be used for routine immunization and other community based interventions. Electronic data collection not only provided the number of children but provided the locations also where these children could be found. Conclusion: Despite the limitations of time to harmonize the micro plans with the national plan, the micro planning process was a great success with 46/47 counties responding through the mobile phone app. Not only did it provide the numbers of the target children, it further provided the places where these children could be found. There was timely data transfer, data integrity, tracking, real time data visualization reporting and analysis. The app enabled real time feedback to national focal point by data entry clerks as well as enabling trouble shooting by the administrator. This ensured campaign planning was done from the lowest level to the national level.
[Mh] Termos MeSH primário: Programas de Imunização/métodos
Vacina contra Sarampo/administração & dosagem
Aplicativos Móveis
Vacina contra Rubéola/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Telefone Celular
Criança
Pré-Escolar
Seres Humanos
Lactente
Quênia
Sarampo/prevenção & controle
Rubéola (Sarampo Alemão)/prevenção & controle
Vacinação
Vacinas Combinadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Measles Vaccine); 0 (Rubella Vaccine); 0 (Vaccines, Combined)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.supp.2017.27.3.11939


  7 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29296150
[Au] Autor:Manakongtreecheep K; Davis R
[Ad] Endereço:Yale University, New Haven, Ct 06520, USA.
[Ti] Título:A review of measles control in Kenya, with focus on recent innovations.
[So] Source:Pan Afr Med J;27(Suppl 3):15, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:eng
[Ab] Resumo:Despite the existence of a highly effective measles vaccine and the decrease in worldwide deaths from measles by more than 79% from the 2000 baseline levels, measles today remains one of the leading causes of vaccine-preventable deaths in the world. The African region is a key player in the global fight against measles. Africa has made tremendous progress in its effort to immunize children and to control the disease, increasing its regional measles vaccination coverage from 56% in 2001 to 85% in 2010. The Republic of Kenya has been a strong follower of the World Health Assembly and Measles Elimination 2020 resolutions, which aims to eliminate measles from the country. Since the beginning of the 21st century, Kenya has faced many challenges, but also aid, in the form of new innovations, in their fight against measles. In 2002, Kenya started its first SIA using A-D syringes, and from 2003-2005, GAVI funded injection safety support (INS) to Kenya, as an effort to scale-up safe injection in sub-Saharan Africa. In 2016, the Kenya introduced Measles-Rubella (MR) combined vaccine in its nationwide SIA campaign, after recognizing that rubella is a disease that must be controlled along with measles. In 2009 and 2012 SIAs, Red Cross volunteers conducted H2H visits to promote immunization as well as document information from the community with regards to immunization, including the current coverage, to campaign management levels. Case-based surveillance, using real-time PCR, measles-specific IgM detection and Epi-link were used to confirm and map measles infection during outbreaks. Alternative serosurveys such as Dried Blood Spot and Urine sample surveys were also tested in Kenya. In 2013 and 2016, two studies were also conducted in Kenya on the use of SMS reminder system for routine immunization. These studies, which showed SMS to significantly improve the vaccination coverage, paved way for use of SMS in a larger scale in Kenya.
[Mh] Termos MeSH primário: Vacina contra Sarampo/administração & dosagem
Sarampo/prevenção & controle
Vacinação/estatística & dados numéricos
[Mh] Termos MeSH secundário: Surtos de Doenças
Seres Humanos
Programas de Imunização/organização & administração
Quênia/epidemiologia
Sarampo/epidemiologia
Vigilância da População
Reação em Cadeia da Polimerase em Tempo Real
Vacinação/tendências
Cobertura Vacinal/tendências
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Measles Vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.supp.2017.27.3.12118


  8 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29296149
[Au] Autor:Biellik RJ; Davis R
[Ad] Endereço:WHO African Regional Measles-Rubella Technical Advisory Group, Geneva.
[Ti] Título:The new World Health Organization recommendation on the 2-dose measles vaccine schedule and the way forward in African Region.
[So] Source:Pan Afr Med J;27(Suppl 3):14, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:eng
[Ab] Resumo:The new W.H.O. recommendation, which drops the coverage criterion for adoption of the 2-dose measles vaccine schedule, makes some African countries eligible for the 2-dose schedule which were previously ineligible. We look at the implications of the new recommendation for Ethiopia and Nigeria, the two largest African countries which are eligible under the new recommendation.
[Mh] Termos MeSH primário: Esquemas de Imunização
Vacina contra Sarampo/administração & dosagem
Sarampo/prevenção & controle
[Mh] Termos MeSH secundário: Etiópia
Seres Humanos
Nigéria
Organização Mundial da Saúde
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Measles Vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.supp.2017.27.3.11611


  9 / 10925 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29296148
[Au] Autor:Masresha B; Luce R; Katsande R; Fall A; Eshetu M; Mihigo R
[Ad] Endereço:World Health Organization, Regional office for Africa, Immunisation and Vaccine Development Program, Brazzaville, Republic of Congo.
[Ti] Título:The effect of targeted wide age range SIAs in reducing measles incidence in the African Region.
[So] Source:Pan Afr Med J;27(Suppl 3):13, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:eng
[Ab] Resumo:Periodic measles supplemental immunisation activities (SIAs) increase population immunity and thereby reduce the pool of accumulated susceptible children. They are typically conducted every 2 - 4 years, and most often target children up to five years of age. Between 2012 and 2015, after surveillance data indicated a shift in the epidemiological profile of measles towards older age groups, 11 countries were supported to conduct wide age range SIAs based on their local epidemiological patterns. Six other countries conducted SIAs with measles-rubella vaccines targeting ages 9 months to 14 years as an initial step of introducing rubella vaccine into the immunization program. In subsequent years, the incidence of confirmed measles dropped significantly in 13 of the 17 countries reviewed. The findings emphasize the importance of well-functioning surveillance systems, and the benefits of using of surveillance data to determine the specific target age-range for periodic SIAs to accelerate progress towards measles elimination.
[Mh] Termos MeSH primário: Programas de Imunização
Imunização/estatística & dados numéricos
Vacina contra Sarampo/administração & dosagem
Sarampo/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
África/epidemiologia
Fatores Etários
Criança
Pré-Escolar
Seres Humanos
Incidência
Lactente
Sarampo/epidemiologia
Vigilância da População
Rubéola (Sarampo Alemão)/prevenção & controle
Vacina contra Rubéola/administração & dosagem
Vacinas Combinadas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Measles Vaccine); 0 (Rubella Vaccine); 0 (Vaccines, Combined)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.supp.2017.27.3.12176


  10 / 10925 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29296146
[Au] Autor:Davis R; Mbabazi WB
[Ad] Endereço:American Red Cross, PO Box 41275-00100, Nairobi, Kenya.
[Ti] Título:Challenges to global measles eradication: is it all in the timing?
[So] Source:Pan Afr Med J;27(Suppl 3):11, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:eng
[Ab] Resumo:The case for global eradication of measles was first made in 1982. Since then, technical aspects of measles eradication have concluded that measles satisfied all criteria required for eradication. To date, only smallpox, among human diseases, has been eradicated, with polio, the next eradication candidate. In all previous eradication programmes, the pattern of slow implementation and missed deadlines is similar. Lessons from these past eradication programs should inform development of a time-limited measles eradication program. Notably, no measles eradication resolution is likely until member states are satisfied that polio eradication is accomplished. However, there is an impetus for measles eradication from the western hemisphere, where governments continue to pay the high costs of keeping their region measles free until global measles eradication is achieved. While previous vaccine preventable diseases eradications have depended on supplemental immunizations (SIAs), measles eradication will have to build both on SIAs and routine immunization systems strengthening. This article reviews non-technical considerations that could facilitate the delivery of a time-limited measles eradication initiative. The issues discussed are categorized as a) specificities of measles disease; b) specifics of measles vaccine/vaccination; c) special considerations for endemic countries and d) organization of international partnerships. The disease and vaccine specific issues are not insurmountable. The introduction of routine measles second dose, in the context of EPI systems strengthening, is paramount to endemic developing countries. In the international partnerships, it should be noted that i) Measles eradication will be easier and cheaper; ii) the return on investment is compelling; iii) leverage is feasible on the experiences of the Measles/Rubella initiative; iv) two disease eradication targets in one initiative are feasible and v) for the first time, an eradication investment case will inform the decisions. However, if previous eradication efforts have been marathons, measles eradication will need to be a sprint.
[Mh] Termos MeSH primário: Erradicação de Doenças
Vacina contra Sarampo/administração & dosagem
Sarampo/prevenção & controle
Vacinação
[Mh] Termos MeSH secundário: Países em Desenvolvimento
Saúde Global
Seres Humanos
Programas de Imunização/organização & administração
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Measles Vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.supp.2017.27.3.12553



página 1 de 1093 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde